Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer.
Document Type
Article
Publication Date
3-1-2018
Publication Title
Acta oncologica (Stockholm, Sweden)
Volume
57
Issue
3
First Page
435
Last Page
437
Recommended Citation
Ding X, Li X, Qin A, Zhou J, Yan D, Stevens C, Krauss D, Kabolizdeh P. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer. Acta Oncol. 2018 Mar;57(3):435-437. doi: 10.1080/0284186X.2017.1358463. Epub 2017 Aug 3. PMID: 28774218.
DOI
10.1080/0284186X.2017.1358463
ISSN
1651-226X
PubMed ID
28774218
COinS